

**How has the APPM developed the recommendations for midazolam dosing in the new formulary?**

Midazolam dosing in paediatric palliative care an area where there has been much debate and discussion through successive formularies. Several pieces of work have informed dosing recommendations in the new formulary including a structured literature review and a survey of professional practice. The results of the midazolam prospective data collection were not published in time for formulary deadlines. The work so far confirms that the research evidence is currently insufficient to make firm recommendations for midazolam dosing in paediatric palliative care for anxiety, agitation at end of life, cerebral irritation or dystonia rescue. Instead, the APPM formulary team has taken a back to basics approach. Dose recommendations in the new APPM formulary are therefore extrapolated, using established pharmacokinetic data and from standard doses adult palliative care, paediatric conscious sedation and paediatric epilepsy quoted in the BNF, BNFC and adult PCF.

Dr Lynda Brook  
Editor, APPM Formulary  
April 2024